Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.54 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.54 |
| ▸ | CCR1 | P32246 | 2/20 | 0.52 |
| ▸ | CCR5 | P51681 | 2/20 | 0.52 |
| ▸ | CCR8 | P51685 | 2/20 | 0.52 |
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.51 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27862604 | 0.98 | KDM4E (0.57) | KDM4EPARP1PSMD14COPS5CCR1 | |
| SCHEMBL1161161 | 0.84 | KDM4E (0.54) | KDM4EPARP1PSMD14COPS5CCR1 | |
| SCHEMBL29242644 | 0.82 | GAA (0.41) | KDM4EPSMD14COPS5CYP1A2MAPT | |
| SCHEMBL29087055 | 0.81 | KDM4E (0.51) | KDM4EPARP1PSMD14COPS5CCR1 | |
| SCHEMBL29084271 | 0.81 | MEN1 (0.40) | KDM4EPSMD14COPS5CYP1A2MAPT | |
| SCHEMBL9084124 | 0.78 | PSMD14 (0.64) | PSMD14COPS5HTT | |
| SCHEMBL29087025 | 0.78 | KDM4E (0.48) | KDM4EPARP1PSMD14COPS5CCR1 | |
| SCHEMBL17773847 | 0.75 | CCR1 (0.63) | KDM4EPARP1PSMD14COPS5CCR1 | |
| SCHEMBL9355371 | 0.75 | PARP1 (0.74) | KDM4EPARP1PSMD14COPS5CCR1 | |
| SCHEMBL11161309 | 0.74 | TTR (0.45) | KDM4ECYP1A2MAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114574062-B | Preparation method of emulsion for water-based paint | 熊海如 | 2023-08-29 | — | — | CN | claimed |
| CN-114479583-B | Preparation method of coating composition | 厦门纬达树脂有限公司 | 2023-01-20 | — | — | CN | claimed |
| CN-114410171-B | Water-based paint | 鹤山市信兴化工有限公司 | 2022-12-06 | — | — | CN | claimed |
| CN-114574062-A | Preparation method of modified fluorine-containing polyacrylate coating | 熊海如 | 2022-06-03 | — | — | CN | claimed |
| CN-114479583-A | Preparation method of coating composition | 熊海如 | 2022-05-13 | — | — | CN | claimed |
| CN-114410171-A | Water-based paint | 熊海如 | 2022-04-29 | — | — | CN | claimed |
| CN-110872252-A | Preparation method of 3-methylquinoline-8-sulfonyl chloride | 北京成宇化工有限公司 | 2020-03-10 | — | — | CN | claimed |
| CN-101454289-B | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicine | ESTEVE LABOR DR | 2012-07-04 | — | — | CN | claimed |
| EP-2007729-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2012-06-27 | — | — | EP | claimed |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-20 | — | — | US | claimed |
| EP-2079701-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-22 | — | — | EP | claimed |
| CN-101454289-A | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicine | ESTEVE LABOR DR (ES) | 2009-06-10 | — | — | CN | claimed |
| EP-2007729-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-12-31 | — | — | EP | claimed |
| WO-2008043544-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-04-17 | — | — | WO | claimed |
| EP-1911747-A1 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | claimed |
| WO-2007107373-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2007-09-27 | — | — | WO | claimed |
| CN-120992790-A | Detection method of potential mutation-causing impurities in Argatroban injection | 康普药业股份有限公司 | 2025-11-21 | — | — | CN | disclosed |
| CN-118191163-A | Determination method of genotoxic impurities in Argatroban raw material | 北京悦康科创医药科技股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
| US-5453430-A | Anticoagulants | SYNTHELABO (FR) | 1995-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | HTR6, HTR5A, HTR7 | KDM4E 3367/4885PARP1 1541/4885PSMD14 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.